SVRASavara Inc.

HealthcareUSD
$5.62

The financials

Savara Inc. by the numbers

Savara Inc. income statement, Q2 2026 against the same quarter a year earlier
Income statementQ2 2026Q2 2025Change
Operating income−$41M−$31Mn/a
Net income−$40M−$30Mn/a
Diluted EPS−$0.16−$0.14n/a

Biotechnology

Ranks #103 of 145 by Smart Score

Compare peers
MNKD+2.3%
MannKind Corporation
AVLN-3.7%
Avalyn Pharma Inc.
COAG-3.6%
Hemab Therapeutics Holdings, Inc.
IMTX-4.9%
Immatics N.V.
JBIO-0.41%
Jade Biosciences, Inc.
EYPT-4.8%
EyePoint, Inc.